Premium
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides
Author(s) -
Di Lorenzo G.,
Di Trolio R.,
Delfino M.,
De Placido S.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06682.x
Subject(s) - mycosis fungoides , medicine , adverse effect , toxicity , stage (stratigraphy) , dermatology , retrospective cohort study , gastroenterology , lymphoma , mycosis , surgery , paleontology , biology
Summary Background Previous studies have shown that pegylated liposomal doxorubicin (LD) is effective in the treatment of relapsing or recalcitrant cutaneous T‐cell lymphoma. Objectives To evaluate the activity and toxicity of LD in patients with stage IVB mycosis fungoides (MF). Methods In this retrospective study, we evaluated outcomes and recorded adverse effects in 10 patients with MF (seven men and three women) with extracutaneous involvement. Patients were treated with LD 20 mg m −2 administered intravenously every 4 weeks. Results All patients received at least two cycles of LD, three patients received four cycles and one patient received six cycles. Three patients (30%) had a partial response and two patients had stable disease. Grade 1–2 leucopenia occurred in three of the 10 patients, and grade 4 leucopenia in one. Three patients had grade 2 palmoplantar erythrodysaesthesia. Conclusions This study demonstrates that LD is beneficial in terms of activity and toxicity in stage IVB MF. These observations should be verified in larger studies.